Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Rifkin

Showing results (1-10 of 26) with videos related to

Pageof 3
Sort By:
Practical Procedures & Aesthetic Dentistry : PPAD|November 17, 2004
Treatment selection for anterior endodontically involved teethRobert Rifkin, Ed McLaren
Journal of the California Dental Association|November 29, 2002
Macroesthetics: facial and dentofacial analysisEdward A McLaren, Robert Rifkin
Clinical Therapeutics|April 30, 2019
Daratumumab Split First Versus Single Dosing Schedule Among Patients With Multiple Myeloma Treated in a US Community Oncology Setting: A Retrospective Observational StudyRobert Rifkin, David Singer, Kathleen M Aguilar, et al.
BMC Neurology|August 10, 2013
Passively transferred human NMO-IgG exacerbates demyelination in mouse experimental autoimmune encephalomyelitisHarleen Saini, Robert Rifkin, Michael Gorelik, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 1, 2010
Pegfilgrastim appears equivalent to daily dosing of filgrastim to treat neutropenia after autologous peripheral blood stem cell transplantation in patients with non-Hodgkin lymphomaRobert Rifkin, Gary Spitzer, Gregory Orloff, et al.
American Journal of Hematology|February 19, 2017
A phase 2 safety study of accelerated elotuzumab infusion, over less than 1 h, in combination with lenalidomide and dexamethasone, in patients with multiple myelomaJames Berenson, Robert Manges, Suprith Badarinath, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|March 18, 2016
A Role for the GIRK3 Subunit in Methamphetamine-Induced Attenuation of GABAB Receptor-Activated GIRK Currents in VTA Dopamine NeuronsMichaelanne B Munoz, Claire L Padgett, Robert Rifkin, et al.
Clinical Therapeutics|February 19, 2019
Cost Offsets in the Treatment Journeys of Patients With Relapsed/Refractory Multiple MyelomaSikander Ailawadhi, Maral DerSarkissian, Mei Sheng Duh, et al.
Cell Transplantation|April 18, 2012
Noninvasive monitoring of immunosuppressive drug efficacy to prevent rejection of intracerebral glial precursor allograftsMichael Gorelik, Miroslaw Janowski, Chulani Galpoththawela, et al.
Frontiers in Oncology|August 14, 2025
A roadmap to implementing outpatient administration of bispecific antibodies in multiple myelomaAlfred L Garfall, Rahul Banerjee, Laurent Frenzel, et al.
Pageof 3

Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
Practical Procedures & Aesthetic Dentistry : PPAD|November 17, 2004
Treatment selection for anterior endodontically involved teethRobert Rifkin, Ed McLaren
Journal of the California Dental Association|November 29, 2002
Macroesthetics: facial and dentofacial analysisEdward A McLaren, Robert Rifkin
Clinical Therapeutics|April 30, 2019
Daratumumab Split First Versus Single Dosing Schedule Among Patients With Multiple Myeloma Treated in a US Community Oncology Setting: A Retrospective Observational StudyRobert Rifkin, David Singer, Kathleen M Aguilar, et al.
BMC Neurology|August 10, 2013
Passively transferred human NMO-IgG exacerbates demyelination in mouse experimental autoimmune encephalomyelitisHarleen Saini, Robert Rifkin, Michael Gorelik, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 1, 2010
Pegfilgrastim appears equivalent to daily dosing of filgrastim to treat neutropenia after autologous peripheral blood stem cell transplantation in patients with non-Hodgkin lymphomaRobert Rifkin, Gary Spitzer, Gregory Orloff, et al.
American Journal of Hematology|February 19, 2017
A phase 2 safety study of accelerated elotuzumab infusion, over less than 1 h, in combination with lenalidomide and dexamethasone, in patients with multiple myelomaJames Berenson, Robert Manges, Suprith Badarinath, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|March 18, 2016
A Role for the GIRK3 Subunit in Methamphetamine-Induced Attenuation of GABAB Receptor-Activated GIRK Currents in VTA Dopamine NeuronsMichaelanne B Munoz, Claire L Padgett, Robert Rifkin, et al.
Clinical Therapeutics|February 19, 2019
Cost Offsets in the Treatment Journeys of Patients With Relapsed/Refractory Multiple MyelomaSikander Ailawadhi, Maral DerSarkissian, Mei Sheng Duh, et al.
Cell Transplantation|April 18, 2012
Noninvasive monitoring of immunosuppressive drug efficacy to prevent rejection of intracerebral glial precursor allograftsMichael Gorelik, Miroslaw Janowski, Chulani Galpoththawela, et al.
Frontiers in Oncology|August 14, 2025
A roadmap to implementing outpatient administration of bispecific antibodies in multiple myelomaAlfred L Garfall, Rahul Banerjee, Laurent Frenzel, et al.
Pageof 3